RxDoctor Payments Data

Antony Chu, MD

Clinical Cardiac Electrophysiology · Bemidji, MNNPI 1063573764

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (41.0%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 13 manufacturers reported payments, led by Medtronic at 29.4% of the total. Reporting peaked in 2022 at $5,681 and has fallen 83.4% since, to $942 in 2025.

$15,931in general payments, 2019–2025

Across 113 payments — averaging $140.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$5K
  • Substrate HD$3K
  • Boston Scientific$2K
  • Volta Medical Inc$2K
  • Biotronik Inc.$1K
  • Abbott$897
  • plus $2K from 7 others
$157,467in research payments, 2019–2025

Across 13 payments — averaging $12,113 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Medtronic$157K
$13,133in ownership & investment interests, 2019–2025

Across 5 payments — averaging $2626.63 each. An ownership or investment interest held by the physician or an immediate family member.

  • Substrate HD$13K

What the payments were for

  • Consulting fees$4,56729%
  • Speaking & faculty fees$6724%
  • Travel & lodging$4,16826%
  • Food & beverage$6,52441%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,931 in reported general payments places this provider in the 60th percentile of 72 clinical cardiac electrophysiology providers in Minnesota.

See all clinical cardiac electrophysiology providers in Minnesota

Medicare billing

Part B allowed, 2024
$82,205
Medicare patients
1,259
Services billed
2,004

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban12$19,731
Flecainide Acetate11$304

Paid to pharmacies, not to this prescriber.

Other clinical cardiac electrophysiology in Bemidji

See the full list for Minnesota

Where these figures come from

Is this you, or does something look wrong? →